Yungjin Pharm

At a glance

Yungjin Pharm filed 33 disclosures in the last 12 months, including 3 earnings and 1 issuance. The most recent key filing was on Jul 31.

Revenue for 2025 was ₩254B, up 0.9% on 2024. Operating margin was 1.3% against 3.5% a year earlier. Debt was 187% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩125B and operating loss of ₩3.3B.

The 2025 annual report lists 626 employees with an average tenure of 10.3 years and average pay of ₩69.3M, #610 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩280M each on average. It paid no cash dividend for 2025. (주)케이티앤지 and related parties held 52.45% at year end.

From the 2025 annual report

Staff: 626 (434 men, 192 women), of whom 42 on fixed-term contracts. Total pay for the year: ₩43.3B. Directors and auditors: 5, paid ₩1.4B in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)케이티앤지 holds 52.45%; with 0 related parties the group holds 52.45% of common shares at year end.

Individuals paid ₩500M or more

Auditor: 한울회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary